Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

AEON gains FDA steer on biosimilar path for botulinum toxin ABP-450

The US company reported a regulatory roadmap for its BOTOX-referencing candidate and about $6.2m from warrant exercises as it published third-quarter results.

16 Nov 2026 · AEON Biopharma, Inc. AEON · Company news

AEON Biopharma has taken in roughly $6.2m from the exercise of milestone warrants and obtained US regulatory feedback on how it might develop ABP-450 as a biosimilar to BOTOX. The company disclosed both on 16 November 2026 with its third-quarter results.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): AEON Biopharma, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →